Drug Trial Radar · NCT03930953
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
438
Planned (sponsor's estimate)
Start
May 20, 2019
Primary completion
Apr 7, 2027
Study completion Feb 9, 2028
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
CC-99282Drug
Specified dose on specified days
RituximabDrug
Specified dose on specified days
ObinutuzumabDrug
Specified dose on specified days
TafasitamabDrug
Specified dose on specified days
ValemetostatDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- Number of participants with laboratory abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- Number of participants with vital sign abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- Number of participants with left ventricular ejection fraction (LVEF) assessment abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- Number of participants with physical examination abnormalitiesTime frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
- Dose Limiting Toxicity (DLT)Time frame: Up to 28 days in Cycle 1
- Maximum tolerated dose (MTD)Time frame: Up to 28 days in cycle 1
Locations
66 sites in 15 countries. Site status is shown where the registry gives one.
Local Institution - 109
Scottsdale, Arizona
Local Institution - 111
Jacksonville, Florida
Local Institution - 102
Tampa, Florida
Local Institution - 108
Overland Park, Kansas
Local Institution - 107
Rochester, Minnesota
Local Institution - 104
St Louis, Missouri
Local Institution - 103
Hackensack, New Jersey
Local Institution - 101
Houston, Texas
Local Institution - 253
Buenos Aires, Argentina
Local Institution - 255
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 254
Pilar, Buenos Aires, Argentina
Local Institution - 701
Salzburg, Austria
Local Institution - 704
Sankt Pölten, Austria
Local Institution - 703
Vienna, Austria
Local Institution - 902
Leuven, Belgium
Local Institution - 451
São Paulo, Brazil
Local Institution - 452
São Paulo, Brazil
Local Institution - 453
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 450
São Paulo, São Paulo, Brazil
Local Institution - 201
Toronto, Ontario, Canada
Local Institution - 354
Santiago, Metropolitana de Santiago, Chile
Local Institution - 350
Santiago, RM, Chile
Local Institution - 355
Recoleta, Santiago Metropolitan, Chile
Local Institution - 353
Santiago, Santiago Metropolitan, Chile
Local Institution - 352
Santiago, Santiago Metropolitan, Chile
Local Institution - 659
Guangzhou, China
Local Institution - 653
Beijing, Beijing Municipality, China
Local Institution - 657
Guangzhou, Guangdong, China
Local Institution - 655
Zhengzhou, Henan, China
Local Institution - 660
Wuhan, Hubei, China
Local Institution - 662
Shenyang, Liaoning, China
Local Institution - 663
Shenyang, Liaoning, China
Local Institution - 650
Shanghai, Shanghai Municipality, China
Local Institution - 651
Tianjin, Tianjin Municipality, China
Local Institution - 602
Aarhus, Denmark
Local Institution - 601
Copenhagen, Denmark
Local Institution - 603
Vejle, Denmark
Local Institution - 407
Bordeaux, France
Local Institution - 403
Créteil, France
Local Institution - 406
Lille, France
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.